Companies › Epsilogen
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MOv18 IgE Anti-folate receptor alpha (FRα) monoclonal antibody of the IgE class | FOLR1 | Phase 1 | Advanced Ovarian Cancer | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06547840 | MOv18 IgE | Phase 1 | Advanced Ovarian Cancer | Oncology | Mar 2027 |
AbbVie Phrontline Biopharma Beijing Biotech Eisai Changchun GeneScience Pharmaceutical Takeda CSPC Megalith Biopharmaceutical AstraZeneca
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.